Faruqi and Faruqui, LLP Logo
Share this page

TriVascular Technologies, Inc. (TRIV)

NasdaqGS:TRIV

Summary

Faruqi & Faruqi, LLP Announces the Investigation of TriVascular Technologies, Inc. (TRIV) Over the Proposed Sale of the Company to Endologix, Inc.

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of TriVascular Technologies, Inc. (“TriVascular” or the “Company”) (NasdaqGS:TRIV) for potential breaches of fiduciary duties in connection with the sale of the Company to Endologix, Inc. for approximately $211 million.

The Company’s stockholders will only receive a combination of cash and stock, to be determined at the closing of the merger, valued at $9.10 for each share of Company common stock they own. However, the offer is lower than at least one analyst’s price target of $13 per share and the April 16, 2014, IPO price of $12 per share.

If you own common stock in TriVascular and wish to obtain additional information and protect your investments free of charge, please fill out the form below or contact Juan Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330. 

Request Information

Please tell us about yourself by completing the form below and we will provide you with additional
information at no cost to you on how to join the Class Action.

  • Company:
    TriVascular Technologies, Inc. (TRIV)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Juan E. Monteverde
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 10/28/2015

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.